Beta-blockers for secondary prevention following myocardial infarction in patients without reduced ejection fraction or heart failure: an updated meta-analysis
Pooled result · All-cause mortalityResult — go to the resultHazard ratio 0.89 95% CI 0.81–0.97Authors' conclusion
In the contemporary reperfusion era, BB may not confer additional mortality benefits beyond a 1-year event-free period post-MI in patients without reduced EF. Moreover, post-MI BB use was associated with detrimental effects in patients with preserved EF.
Study context
- Population
- MI patients without reduced ejection fraction (EF) (≤40%) or history of heart failure (HF), contemporary studies 2000–2024
- Participants
- 290,349 patients24 studies
- Comparison
- Beta-blocker (BB) users vs non-users post-MI
- Outcome
- All-cause mortality
Methodological detailsrandom-effects, pre-specified subgroup analyses, meta-regression
- Random-effects
- Pre-specified subgroup analyses
- Meta-regression
Pooled result
As reported in the abstract
Hazard ratio
0.89
95% CI 0.81–0.97
BBvs Non-users
HR 0.89 (95% CI 0.81–0.97)
Further pooled results
All-cause mortality, patients with no event-free period (meta-regression)
- BB mortality benefits modified by study inclusion period (decreasing over time)
- P = 0.01
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Beta-blockers for secondary prevention following myocardial infarction in patients without reduced ejection fraction or heart failure: an updated meta-analysis. Eur J Prev Cardiol. Published 20 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →